Skip to main content
. 2018 Jun 14;19:138. doi: 10.1186/s12882-018-0933-2

Table 1.

Clinical characteristics of AAV patients complicated with or without infection

AAV
(n = 248)
Infection group
(n = 86)
Non-infection group
(n = 162)
P
Age(ys) 55.0 (42.8~ 64.0) 58.0 (46.8~ 66.0) 54.0 (40.0~ 63.0) 0.082
male, n(%) 103 (41.5) 40 (46.5) 63 (38.9) 0.155
smoke, n(%) 59 (23.8) 31 (36.0) 28 (17.3) 0.000**
Diabetes, n(%) 11 (4.4) 7 (8.1) 4 (2.5) 0.032*
MPO-ANCA, n(%) 227 (91.5) 79 (91.9) 148 (91.4) 0.968
PR3-ANCA, n(%) 21 (8.5) 7(8.1) 14 (8.6) 0.968
Hemoglobin (g/dl) 8.5 (7.4~ 9.7) 8.2 (6.7~ 9.2) 8.8 (7.7~ 9.9) 0.004**
White blood cell (/mm3) 7200.0
(5000.0~ 10,000.0)
7600.0
(5900.0~ 11,350.0)
6900.0
(4900.0~ 9750.0)
0.049*
Albumin (g/l) 35.5 (31.6~ 38.7) 33.8 (30.3~ 36.9) 35.9 (32.4~ 39.6) 0.002*
Globulin (g/l) 27.4 (23.4~ 32.2) 26.8 (22.3~ 33.1) 27.6 (23.5~ 31.6) 0.761
Creatinine (mg/dl) 3.3 (1.8~ 5.3) 4.16 (2.5~ 6.9) 2.8 (1.5~ 4.7) 0.000**
eGFR< 60 ml/min per 1.73m2, n(%) 216 (87.1) 81 (94.2) 135 (83.3) 0.000**
CD4 lympnocyte cell(/ul) 416.0 (234.5~ 589.8) 399.0 (207.5~ 552.0) 428.0 (258.0~ 662.0) 0.027*
IgG (g/l) 13.3 (10.4~ 16.4) 13.4 (10.4~ 16.5) 12.9 (10.3~ 16.3) 0.570
C3 (g/l) 0.9 (0.8~ 1.1) 0.9 (0.8~ 1.2) 0.9 (0.8~ 1.1) 0.569
Lung involvement, n(%) 75 (30.2) 34 (39.5) 41 (25.3) 0.011**
BVAS 14 (12~ 16) 15 (12~ 17) 14 (12~ 16) 0.009**
MP pulse therapy, n(%) 167 (67.3) 56 (65.1) 111 (68.5) 0.929
Plasma exchanage, n(%) 59 (23.8) 25 (29.1) 34 (20.9) 0.109
Induction therapy
 corticosteroids only, n(%) 65 (26.2) 25 (29.1) 40 (24.7) 0.349
 corticosteroids+CYC, n(%) 66 (26.6) 26 (30.2) 44 (27.2) 0.938
 corticosteroids+MMF, n(%) 77 (31.0) 26 (30.2) 47 (29.0) 0.245
 corticosteroids+TW, n(%) 40 (16.1) 9 (10.5) 31 (19.1) 0.052

**P < 0.01; *P < 0.05, IgG Immunoglobulin G, BVAS Birmingham vasculitis activity score, MP Methlyprednisone, CYC Cyclophosphamide, MMF Mycophenolate mofetil